189 related articles for article (PubMed ID: 29405437)
1. Studying the effect of systemic and biological drugs on intima-media thickness in patients suffering from moderate and severe psoriasis.
Martinez-Lopez A; Blasco-Morente G; Perez-Lopez I; Tercedor-Sanchez J; Arias-Santiago S
J Eur Acad Dermatol Venereol; 2018 Sep; 32(9):1492-1498. PubMed ID: 29405437
[TBL] [Abstract][Full Text] [Related]
2. Impact of effective tumor necrosis factor-alfa inhibitor treatment on arterial intima-media thickness in psoriasis: results of a pilot study.
Jókai H; Szakonyi J; Kontár O; Marschalkó M; Szalai K; Kárpáti S; Holló P
J Am Acad Dermatol; 2013 Oct; 69(4):523-9. PubMed ID: 23891393
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular outcomes and systemic anti-inflammatory drugs in patients with severe psoriasis: 5-year follow-up of a Danish nationwide cohort.
Ahlehoff O; Skov L; Gislason G; Gniadecki R; Iversen L; Bryld LE; Lasthein S; Lindhardsen J; Kristensen SL; Torp-Pedersen C; Hansen PR
J Eur Acad Dermatol Venereol; 2015 Jun; 29(6):1128-34. PubMed ID: 25303139
[TBL] [Abstract][Full Text] [Related]
4. Analysis of cardiovascular risk and carotid intima-media thickness in patients with psoriasis.
Abrahão-Machado ECF; Mendonça JA; Arruda ACBB; Nucci LB; Santos MASD
An Bras Dermatol; 2020; 95(2):150-157. PubMed ID: 32122693
[TBL] [Abstract][Full Text] [Related]
5. Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry.
Fiorentino D; Ho V; Lebwohl MG; Leite L; Hopkins L; Galindo C; Goyal K; Langholff W; Fakharzadeh S; Srivastava B; Langley RG
J Am Acad Dermatol; 2017 Nov; 77(5):845-854.e5. PubMed ID: 28893407
[TBL] [Abstract][Full Text] [Related]
6. Effects of tumor necrosis factor-α, interleukin-23 and interleukin-17A inhibitors on bodyweight and body mass index in patients with psoriasis.
Takamura S; Takahashi A; Inoue Y; Teraki Y
J Dermatol; 2018 Sep; 45(9):1130-1134. PubMed ID: 30004583
[TBL] [Abstract][Full Text] [Related]
7. Sitagliptin Attenuates the Progression of Carotid Intima-Media Thickening in Insulin-Treated Patients With Type 2 Diabetes: The Sitagliptin Preventive Study of Intima-Media Thickness Evaluation (SPIKE): A Randomized Controlled Trial.
Mita T; Katakami N; Shiraiwa T; Yoshii H; Onuma T; Kuribayashi N; Osonoi T; Kaneto H; Kosugi K; Umayahara Y; Yamamoto T; Matsumoto K; Yokoyama H; Tsugawa M; Gosho M; Shimomura I; Watada H;
Diabetes Care; 2016 Mar; 39(3):455-64. PubMed ID: 26822324
[TBL] [Abstract][Full Text] [Related]
8. Efficacy comparison of ustekinumab between anti-tumor necrosis factor-α drug-naïve and anti-tumor necrosis factor-α drug-resistant Japanese psoriasis cases.
Takahashi N; Noda S; Taniguchi T; Adachi M
Int J Dermatol; 2015 Oct; 54(10):1194-8. PubMed ID: 26016819
[TBL] [Abstract][Full Text] [Related]
9. Rheumatoid arthritis is an independent risk factor for increased carotid intima-media thickness: impact of anti-inflammatory treatment.
Ristić GG; Lepić T; Glisić B; Stanisavljević D; Vojvodić D; Petronijević M; Stefanović D
Rheumatology (Oxford); 2010 Jun; 49(6):1076-81. PubMed ID: 20208070
[TBL] [Abstract][Full Text] [Related]
10. Long-term anti-tumour necrosis factor therapy reverses the progression of carotid intima-media thickness in female patients with active rheumatoid arthritis.
Ferrante A; Giardina AR; Ciccia F; Parrinello G; Licata G; Avellone G; Giardina E; Impastato R; Triolo G
Rheumatol Int; 2009 Dec; 30(2):193-8. PubMed ID: 19387646
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Risk of Major Adverse Cardiovascular Events With Biologic Therapy in Patients With Psoriasis.
Bissonnette R; Kerdel F; Naldi L; Papp K; Galindo C; Langholff W; Tang KL; Szapary P; Fakharzadeh S; Srivastava B; Goyal K; Gottlieb AB
J Drugs Dermatol; 2017 Oct; 16(10):1002-1013. PubMed ID: 29036254
[TBL] [Abstract][Full Text] [Related]
12. Intima-media thickness in an Italian psoriatic population: correlation with lipidic serum levels, PASI and BMI.
Antonucci VA; Tengattini V; Balestri R; Patrizi A; Filippini M; Bardazzi F
J Eur Acad Dermatol Venereol; 2014 Apr; 28(4):512-5. PubMed ID: 23279329
[TBL] [Abstract][Full Text] [Related]
13. Histone modifications associated with biological drug response in moderate-to-severe psoriasis.
Ovejero-Benito MC; Reolid A; Sánchez-Jiménez P; Saiz-Rodríguez M; Muñoz-Aceituno E; Llamas-Velasco M; Martín-Vilchez S; Cabaleiro T; Román M; Ochoa D; Daudén E; Abad-Santos F
Exp Dermatol; 2018 Dec; 27(12):1361-1371. PubMed ID: 30260532
[TBL] [Abstract][Full Text] [Related]
14. Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis.
Garber C; Plotnikova N; Au SC; Sorensen EP; Gottlieb A
J Drugs Dermatol; 2015 Aug; 14(8):846-52. PubMed ID: 26267729
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetics and Pharmacogenomics in Moderate-to-Severe Psoriasis.
Ovejero-Benito MC; Muñoz-Aceituno E; Reolid A; Saiz-Rodríguez M; Abad-Santos F; Daudén E
Am J Clin Dermatol; 2018 Apr; 19(2):209-222. PubMed ID: 28921458
[TBL] [Abstract][Full Text] [Related]
16. Intima-media thickness of brachial artery, vascular function, and cardiovascular risk factors.
Iwamoto Y; Maruhashi T; Fujii Y; Idei N; Fujimura N; Mikami S; Kajikawa M; Matsumoto T; Kihara Y; Chayama K; Noma K; Nakashima A; Higashi Y
Arterioscler Thromb Vasc Biol; 2012 Sep; 32(9):2295-303. PubMed ID: 22796580
[TBL] [Abstract][Full Text] [Related]
17. Development of clinical prediction models for good or bad response to classic systemic drugs, anti-TNFs, and ustekinumab in psoriasis, based on the BIOBADADERM cohort.
García-Doval I; Pérez-Zafrilla B; Ferrandiz C; Carretero G; Daudén E; de la Cueva P; Gómez-García FJ; Herrera-Ceballos E; Belinchón-Romero I; Sánchez-Carazo JL; López-Estebaranz JL; Alsina M; Ferrán M; Torrado R; Carrascosa JM; Rivera R; Vanaclocha F;
J Dermatolog Treat; 2016; 27(3):203-9. PubMed ID: 26367799
[TBL] [Abstract][Full Text] [Related]
18. Biologic drug survival in Israeli psoriasis patients.
Shalom G; Cohen AD; Ziv M; Eran CB; Feldhamer I; Freud T; Berman E; Oren S; Hodak E; Pavlovsky L
J Am Acad Dermatol; 2017 Apr; 76(4):662-669.e1. PubMed ID: 28038888
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real-world cohort study.
Ahlehoff O; Skov L; Gislason G; Lindhardsen J; Kristensen SL; Iversen L; Lasthein S; Gniadecki R; Dam TN; Torp-Pedersen C; Hansen PR
J Intern Med; 2013 Feb; 273(2):197-204. PubMed ID: 22963528
[TBL] [Abstract][Full Text] [Related]
20. From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies.
Hugh J; Van Voorhees AS; Nijhawan RI; Bagel J; Lebwohl M; Blauvelt A; Hsu S; Weinberg JM
J Am Acad Dermatol; 2014 Jan; 70(1):168-77. PubMed ID: 24184141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
